Literature DB >> 19393192

Cardiovascular risk in rheumatoid arthritis.

Michael T Nurmohamed1.   

Abstract

The increased mortality in rheumatoid arthritis (RA) is mainly due to (atherosclerotic) cardiovascular disease. The cardiovascular morbidity is also increased in comparison with the general population. This increased cardiovascular burden could be caused by 1) an enhanced prevalence of cardiovascular risk factors 2) under treatment of cardiovascular risk factors or 3) RA itself, particularly due to its chronic inflammatory component. Cardiovascular risk factors only partially explain the increased cardiovascular risk and it is becoming increasingly acknowledged that the underlying inflammation in RA plays an essential role. This is probably related to the fact that atherosclerosis also has an inflammatory etiology that is accelerated by RA. Similarly, it can be expected that effective suppression of this inflammatory process by disease modifying antirheumatic drugs and/or biologicals lowers the cardiovascular risk. Altogether, there is accumulating evidence that the increased cardiovascular risk in RA is comparable to that of type 2 diabetes and actually RA should be seen as a new, independent, cardiovascular risk factor for which cardiovascular risk management is essential.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19393192     DOI: 10.1016/j.autrev.2009.02.015

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  33 in total

1.  Cardiovascular injury in systemic autoimmune diseases: an update.

Authors:  Maurizio Turiel; Piercarlo Sarzi-Puttini; Fabiola Atzeni; Vito De Gennaro Colonna; Luigi Gianturco; Livio Tomasoni
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

2.  Effects of simvastatin on the function of dendritic cells in patients with rheumatic arthritis.

Authors:  Yuhong Liu; Shasha Wang; Lingxun Shen; Yulan Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

3.  Are NSAIDs safe to use in post-MI patients?

Authors:  Michael T Nurmohamed
Journal:  Nat Rev Rheumatol       Date:  2011-08-02       Impact factor: 20.543

4.  Prevalence of dyslipidemia in Japanese patients with rheumatoid arthritis and effects of atorvastatin treatment.

Authors:  Mio Akiyama; Taro Mawatari; Yasuharu Nakashima; Hisaaki Miyahara; Hisakata Yamada; Ken Okazaki; Jun-ichi Fukushi; Masakazu Kondo; Junji Kishimoto; Chinami Hashimura; Yukihide Iwamoto
Journal:  Clin Rheumatol       Date:  2015-08-21       Impact factor: 2.980

Review 5.  The role of endothelial function and its assessment in rheumatoid arthritis.

Authors:  Faisel Khan; Bernat Galarraga; Jill J F Belch
Journal:  Nat Rev Rheumatol       Date:  2010-03-30       Impact factor: 20.543

6.  Carotid artery intima-media thickness in patients with autoimmune connective tissue diseases: a case-control study.

Authors:  Vincenzo Bruzzese; Cinzia Marrese; Angelo Zullo; Cesare Hassan; Lorenzo Ridola; Annamaria Izzo; Camillo Riccioni
Journal:  Intern Emerg Med       Date:  2011-10-28       Impact factor: 3.397

Review 7.  Vascular effects of biologic agents in RA and spondyloarthropathies.

Authors:  Zoltán Szekanecz; György Kerekes; Pál Soltész
Journal:  Nat Rev Rheumatol       Date:  2009-11-10       Impact factor: 20.543

8.  Vitamin B-6 intake is inversely related to, and the requirement is affected by, inflammation status.

Authors:  Martha Savaria Morris; Lydia Sakakeeny; Paul F Jacques; Mary Frances Picciano; Jacob Selhub
Journal:  J Nutr       Date:  2009-11-11       Impact factor: 4.798

Review 9.  Rheumatoid arthritis and metabolic syndrome.

Authors:  György Kerekes; Michael T Nurmohamed; Miguel A González-Gay; Ildikó Seres; György Paragh; Zsófia Kardos; Zsuzsa Baráth; László Tamási; Pál Soltész; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2014-08-05       Impact factor: 20.543

10.  Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells.

Authors:  Carolyn M Summers; Andrea L Hammons; Jasbir Arora; Suhong Zhang; Jeanine Jochems; Ian A Blair; Alexander S Whitehead
Journal:  Eur J Pharmacol       Date:  2014-03-18       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.